Gevo (NASDAQ: GEVO)‘s stock had its “buy” rating restated by analysts at Canaccord Genuity in a research report issued to clients and investors on Monday.
Separately, analysts at Cowen initiated coverage on shares of Gevo in a research note to investors on Wednesday, February 15th. They set a “neutral” rating on the stock.
Gevo traded up 3.61% on Monday, hitting $10.04. Gevo has a 52-week low of $5.18 and a 52-week high of $20.92. The company’s market cap is $262.0 million.
The company last announced its quarterly results on Tuesday, February 28th. It reported ($0.54) earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of ($0.48) EPS by $0.06. The company’s quarterly revenue was up 22.0% on a year-over-year basis. Analysts expect that Gevo will post $-0.57 EPS next quarter.
Gevo, Inc. is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks.